TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26993869

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation at a current twice their motor threshold, at 1 Hz, for 5 minutes.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (nonstimulated side)
Number of subjects: 12
Study: 26994130

Group type: EXPERIMENTAL
Intervention: Mortality risk acceptance during AVR
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Acceptance of prohibitive risk willingness (>50%)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Increasing score on EuroQol-Visual Analog Scale
Number of subjects: 439
Study: 26994231

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Diabetic patients with decreased pain sensation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Diabetic patients requiring more than 0.5 mA to evoke a motor response
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Slowed ulnar nerve conduction velocity
Number of subjects: 107
Study: 26994848

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 4
Study: 26995233

Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1563
Study: 26995365

Group type: EXPERIMENTAL
Intervention: Endovascular device interventions in symptomatic lower extremity PAD
Number of subjects: 1200
Study: 26995690

Group type: EXPERIMENTAL
Intervention: Digital single-operator cholangiopancreatoscopy (SOC)
Number of subjects: 105
Study: 26998310

Group type: EXPERIMENTAL
Intervention: Genetic testing interest among parents
Number of subjects: 320

Group type: COMPARATOR
Intervention: South Asian parents
Number of subjects: 320

Group type: COMPARATOR
Intervention: East/Southeast Asian parents
Number of subjects: 320

Group type: COMPARATOR
Intervention: Immigrants to Canada
Number of subjects: 320

Group type: COMPARATOR
Intervention: Higher education level
Number of subjects: 320
Study: 26998355

Group type: EXPERIMENTAL
Intervention: 1.6 grams of plant stanols
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 2.0 grams of plant stanols
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 1.6 grams of plant stanols with camelina oil
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 2.0 grams of plant stanols with camelina oil
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo minidrink (no plant stanols or camelina oil)
Number of subjects: 143
Study: 26998426

Group type: EXPERIMENTAL
Intervention: CT+G (chemotherapy plus goserelin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT (chemotherapy only)
Number of subjects: 0
Study: 26999488

Group type: EXPERIMENTAL
Intervention: Antiangiogenic therapy
Number of subjects: 10
Study: 27000099

Group type: EXPERIMENTAL
Intervention: FSA-NPS DI (continuous and sex-specific quartiles)
Number of subjects: 6515

Group type: EXPERIMENTAL
Intervention: FSA-NPS DI in smokers
Number of subjects: 6515

Group type: EXPERIMENTAL
Intervention: FSA-NPS DI in physically inactive individuals
Number of subjects: 6515
Study: 27000348

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27000446

Group type: EXPERIMENTAL
Intervention: RT + mCIT
Number of subjects: 34

Group type: COMPARATOR
Intervention: RT
Number of subjects: 34
Study: 27000643

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control (no NSAIDs)
Number of subjects: 178
Study: 27001664

Group type: EXPERIMENTAL
Intervention: High intensity training (HIT) program for 9 weeks
Number of subjects: 79
Study: 27001822

Group type: EXPERIMENTAL
Intervention: M-EDTA-EtOH lock solution administered once daily for 2 hours for a total of 7 doses.
Number of subjects: 30

Group type: COMPARATOR
Intervention: CVC removal and reinsertion (control group).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: M-EDTA-EtOH lock solution.
Number of subjects: 30
Study: 27002141

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 (S3)
Number of subjects: 94

Group type: COMPARATOR
Intervention: SAPIEN XT (S-XT)
Number of subjects: 94
Study: 27002157

Group type: EXPERIMENTAL
Intervention: eIF2α-P activation
Number of subjects: 0
Study: 27002214

Group type: EXPERIMENTAL
Intervention: Healthy weight infants (WFL percentile at the fifth to ≤95)
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Overweight infants (WFL percentile >95th)
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Healthy weight infants
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Mothers who were overweight
Number of subjects: 1416
Study: 27002421

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2164
Study: 27002703

Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Perceived stress and positive emotional eating
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Anhedonia
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 65
Study: 27003363

Group type: EXPERIMENTAL
Intervention: Pazopanib plus CapeOx (capecitabine 850 mg/m2 bid, day 1-14; oxaliplatin 130 mg/m2, day 1; pazopanib 800 mg, day 1-21)
Number of subjects: 66
Study: 27003553

Group type: EXPERIMENTAL
Intervention: Patient-reported bowel movements (BMs) per week at baseline: 3.7 (SD 2.9)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Patient-reported spontaneous bowel movements per week at baseline: 1.4 (SD 2.3)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Patient-reported gastrointestinal-related symptoms of at least moderate intensity at baseline: 97%
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Patient-reported gastrointestinal-related symptoms of at least moderate intensity at week 24: 82%
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Agreement between HCPs and patients on the presence of constipation at baseline: 61%
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Average pain ratings at week 24: HCPs 5.9 vs. patients 6.0
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Patients who spoke to HCPs about constipation in the past month: 63%
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Patients whose HCPs asked about constipation in the past month: 62%
Number of subjects: 489
Study: 27003573

Group type: EXPERIMENTAL
Intervention: 23mm valve (N = 77)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 26mm valve (N = 91)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 29mm valve (N = 67)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: All valve sizes
Number of subjects: 235
Study: 27004234

Group type: EXPERIMENTAL
Intervention: Oral fluid collection for antibody detection
Number of subjects: 0
Study: 27004241

Group type: EXPERIMENTAL
Intervention: Day-3 subgroup (72-hour PPI infusion)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Day-2 subgroup (one day early PPI infusion)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Endoscopic epinephrine-injection monotherapy
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia < 3.0 g/dL
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Forrest Ia-Ib type
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia < 3.5 g/dL
Number of subjects: 316
Study: 27004243

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ)
Number of subjects: 26
Study: 27004426

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 40
Study: 27004532

Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium 0.06 mmol/kg
Number of subjects: 28
Study: 27004552

Group type: EXPERIMENTAL
Intervention: Caring touch (tactile massage and healing touch)
Number of subjects: 41
Study: 27004905

Group type: EXPERIMENTAL
Intervention: TTIP-PRO (tailored telephone intervention delivered by peers)
Number of subjects: 8
Study: 27005892

Group type: EXPERIMENTAL
Intervention: Autologous cell therapy using CD133+ bone marrow-derived stem cells (BMDSCs) in conjunction with hormonal replacement therapy
Number of subjects: 18
Study: 27006491

Group type: EXPERIMENTAL
Intervention: Nilotinib therapy
Number of subjects: 48
Study: 27006492

Group type: EXPERIMENTAL
Intervention: TIL infusion followed by attenuated doses of IL2 administered in an intravenous, continuous decrescendo regimen
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TIL infusion followed by attenuated doses of IL2
Number of subjects: 25
Study: 27006728

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly plus methotrexate for 24 weeks, continued for 104 weeks; total exposure 798.1 patient-years.
Number of subjects: 386

Group type: COMPARATOR
Intervention: Conventional DMARD (hydroxychloroquine or sulfasalazine) plus methotrexate for 24 weeks, followed by treatment modification.
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Etanercept (continued or added) in the treatment regimen after week 24.
Number of subjects: 386
Study: 27007958

Group type: EXPERIMENTAL
Intervention: Incretin-based drugs (DPP-4 inhibitors and GLP-1 analogues)
Number of subjects: 1499650

Group type: COMPARATOR
Intervention: Oral antidiabetic-drug combinations
Number of subjects: 1499650
Study: 27007959

Group type: COMPARATOR
Intervention: Dengue vaccine efficacy (control group)
Number of subjects: 10363
Study: 27008504

Group type: EXPERIMENTAL
Intervention: YouGrabber® system (YouRehab AG, Zurich, Switzerland)
Number of subjects: 15
Study: 27008687

Group type: EXPERIMENTAL
Intervention: Surgical intervention (placebo-controlled)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: General anaesthesia or sedation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Double-blinded trials
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Single-blinded trials
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Completion of study
Number of subjects: 63
Study: 27008892

Group type: EXPERIMENTAL
Intervention: 5 h oral glucose tolerance test (5 h OGTT)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5 h AUC insulin and C-peptide
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5 h AUC C-peptide/insulin
Number of subjects: 122

Group type: COMPARATOR
Intervention: 5 h AUC insulin and C-peptide in lean patients with RH
Number of subjects: 122
Study: 27009059

Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ) schedule A at 0.7 mg/m(2) infused over 10 minutes, administered to 32 patients.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ) schedule B at 0.5 mg/m(2) infused over 2 hours, administered to 36 patients.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ) overall (both schedules).
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Adverse events related to Marizomib.
Number of subjects: 68
Study: 27009082

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 12
Study: 27009092

Group type: EXPERIMENTAL
Intervention: Adjuvant aromatase inhibitors (AIs)
Number of subjects: 494
Study: 27009168

Group type: EXPERIMENTAL
Intervention: Circulating desmosine (pDES) in COPD patients
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Circulating desmosine (pDES) in COPD patients with cardiovascular disease
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 1177
Study: 27009167

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis subjects with previous Pseudomonas aeruginosa infection
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cystic fibrosis subjects without Pseudomonas aeruginosa
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis subjects
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control subjects from a previously reported study
Number of subjects: 51
Study: 27009439

Group type: EXPERIMENTAL
Intervention: Chitosan processed wine
Number of subjects: 0
Study: 27009547

Group type: EXPERIMENTAL
Intervention: Comorbid Major Depressive Disorder (MDD)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Comorbid Anxiety Disorder (AnxD)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Substance-Induced Depression (SID)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Comorbidities (MDD, SID, AnxD)
Number of subjects: 443
Study: 27010542

Group type: EXPERIMENTAL
Intervention: Primaquine (single dose 0.25 mg base/kg)
Number of subjects: 819
Study: 27011794

Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D for six months
Number of subjects: 7
Study: 27012243

Group type: EXPERIMENTAL
Intervention: CKD progression (primary endpoint)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Development of left ventricular hypertrophy or hypertension (secondary outcome)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Impairment of growth (secondary outcome)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Neuropsychological status (secondary outcome)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Behavioral status (secondary outcome)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Kidney growth (secondary outcome)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Quality of life (secondary outcome)
Number of subjects: 450
Study: 27012629

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (3600mg/day EPA/DHA for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 27012891

Group type: EXPERIMENTAL
Intervention: Temporary inferior vena cava (IVC) filters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercially available IVC filters (both temporary and permanent)
Number of subjects: 0
Study: 27013022

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Non-Dexamethasone (N-DXM)
Number of subjects: 92
Study: 27013155

Group type: EXPERIMENTAL
Intervention: DESolve novolimus-eluting bioresorbable coronary scaffold
Number of subjects: 126
Study: 27013162

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27013249

Group type: EXPERIMENTAL
Intervention: High-resolution two-dimensional (2D) speckle tracking echocardiography (STE)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Feature tracking echocardiography (FT-E)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Feature tracking cardiac magnetic resonance imaging (FT-CMR)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Ejection fraction (EF)
Number of subjects: 47
Study: 27013512

Group type: EXPERIMENTAL
Intervention: Monthly follow-up without treatment of asymptomatic mono or mixed P. falciparum infections (24 participants)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Participants with P. vivax mono-infection (34 participants)
Number of subjects: 1447
Study: 27014033

Group type: EXPERIMENTAL
Intervention: Diamond-based electrodes
Number of subjects: 4

Group type: COMPARATOR
Intervention: Carbon fiber electrodes
Number of subjects: 4
Study: 27015087

Group type: EXPERIMENTAL
Intervention: Armolipid Plus (AP) supplementation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 27015233

Group type: EXPERIMENTAL
Intervention: ICU Mobility Scale (IMS) at ICU discharge
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: ICU Mobility Scale (IMS) from study enrollment to ICU discharge
Number of subjects: 192
Study: 27015392

Group type: EXPERIMENTAL
Intervention: Indwelling tunneled pleural catheters (ITPCs)
Number of subjects: 24
Study: 27015562

Group type: EXPERIMENTAL
Intervention: Pemetrexed + Sorafenib
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Inhibition of ERBB1/2/4
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lapatinib or Vandetanib (5 day transient exposure)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Afatinib (ERBB1/2/4 inhibitor)
Number of subjects: 33
Study: 27015798

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (EART) based on lopinavir/r
Number of subjects: 217

Group type: COMPARATOR
Intervention: Not applicable (non-inclusion reasons)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: EART initiation
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Disclosure of HIV status to father
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Age older than 12 months
Number of subjects: 217
Study: 27016248

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Difficulties in Emotion Regulation Questionnaire
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Beck Anxiety Inventory
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Attention Control Scale
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Experimental computer-based attentional control task
Number of subjects: 112
Study: 27018175

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study: 27018703

Group type: EXPERIMENTAL
Intervention: Nitroglycerin Ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27018841

Group type: EXPERIMENTAL
Intervention: HIV+
Number of subjects: 92
Study: 27018988

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin for 48 weeks
Number of subjects: 3181
Study: 27019674

Group type: EXPERIMENTAL
Intervention: COPD patients during exercise echocardiography and cardiopulmonary exercise testing (CPET)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: COPD patients at rest
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: COPD patients at peak exercise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-COPD subjects (controls) at rest
Number of subjects: 27

Group type: COMPARATOR
Intervention: Non-COPD subjects (controls) at peak exercise
Number of subjects: 27
Study: 27019745

Group type: EXPERIMENTAL
Intervention: Cognitive training application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile-sensing application promoting daily activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27020111

Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy (RT) - 25 Gy in 5 daily intensity modulated RT fractions over 1 week
Number of subjects: 32
Study: 27020720

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 316
Study: 27021379

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (ABMNC) therapy
Number of subjects: 21
Study: 27021538

Group type: EXPERIMENTAL
Intervention: 0.50% chlorhexidine (CHX) gel applied using individual trays (3DS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.50% chlorhexidine (CHX) gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: untreated brackets
Number of subjects: 20
Study: 27021967

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (mean dose 195.6 ± 154.8 mg/day)
Number of subjects: 665
Study: 27022067

Group type: EXPERIMENTAL
Intervention: Apatorsen (OGX-427) administered i.v. weekly in 21-day cycles following 3 loading doses and over 5 dose levels (200-1000 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Apatorsen (OGX-427)
Number of subjects: 42
Study: 27022477

Group type: EXPERIMENTAL
Intervention: Radial retinotomy with endodiathermy
Number of subjects: 9
Study: 27022956

Group type: EXPERIMENTAL
Intervention: Intervention group (71 caregivers)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 153
Study: 27025160

Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg/d on days 1-14) plus bortezomib (1.3 mg/m² intravenously on days 1, 4, 8, and 11)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 0
Study: 27025399

Group type: EXPERIMENTAL
Intervention: Rise intervention (treatment education adherence intervention) consisting of 6-10 individual counseling sessions over 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group) for 6 months.
Number of subjects: 0
Study: 27025436

Group type: EXPERIMENTAL
Intervention: Transcatheter interatrial shunt device (IASD)
Number of subjects: 68
Study: 27025608

Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878) 200 mg BID
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878) 400 mg BID (RP2D)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878) 200-600 mg BID
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: VS-6063 (defactinib, PF-04554878)
Number of subjects: 9
Study: 27025825

Group type: EXPERIMENTAL
Intervention: Lyme disease patients (natural history study)
Number of subjects: 101
Study: 27026379

Group type: EXPERIMENTAL
Intervention: Portal vein thrombosis (PVT) patients (n=126; 17% prevalence)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Patients with previous portal vein thrombosis
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Patients with Child-Pugh Class B+C
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Patients with hepatocellular carcinoma
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Patients with previous upper gastrointestinal bleeding
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Patients with portal vein thrombosis not treated with anticoagulant therapy
Number of subjects: 753
Study: 27027250

Group type: EXPERIMENTAL
Intervention: Translated Gene Expression Profiling (GEP) risk signatures
Number of subjects: 126
Study: 27028025

Group type: EXPERIMENTAL
Intervention: Glycaemic control (mean HbA1c)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Adjusted clinical covariates (age, DCCT cohort assignment, DCCT treatment arm, BMI, insulin dosage, parity, hysterectomy, autonomic neuropathy, urinary tract infection in the last year)
Number of subjects: 64
Study: 27028469

Group type: EXPERIMENTAL
Intervention: Patient report
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Automated chart review
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Manual chart review
Number of subjects: 1578
Study: 27028666

Group type: EXPERIMENTAL
Intervention: Prophylactic gastrostomy tube (PGT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Nutritional counselling with a therapeutic feeding tube if required (Control)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Quality of life (FACT-H&N score)
Number of subjects: 95